- Home
- VYNE vs QNRX Comparison
VYNE vs QNRX Comparison
Compare VYNE & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | QNRX |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | VYNE | QNRX |
|---|---|---|
| Price | $0.41 | $12.25 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 892.9K | 154.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.29 | N/A |
| 52 Week Low | $0.28 | $5.01 |
| 52 Week High | $4.30 | $41.80 |
Technical Indicators
Market Signals| Indicator | VYNE | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.95 | 42.32 |
| Support Level | $0.37 | $11.48 |
| Resistance Level | $0.39 | $15.45 |
| Average True Range (ATR) | 0.03 | 2.60 |
| MACD | 0.00 | -1.05 |
| Stochastic Oscillator | 87.95 | 11.54 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.